# A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma

Source: https://onco.cc/trials/nct05972720/  
OnCo record `nct05972720` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Firicabtagene autoleucel run by CARGO Therapeutics, terminated.

## Summary

A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma is a phase 2 interventional study registered as NCT05972720 by CARGO Therapeutics, with 101 participants enrolled, started 2023-08-01. Conditions recorded: Cancer and Relapsed/Refractory Large B-cell Lymphoma (LBCL). Interventions recorded: Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy) and firi-cel (Experimental drug).

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05972720
- Phase: 2
- Setting: An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of Firi-cel, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma After CD19-directed CAR T-cell Therapy
- Sponsor: CARGO Therapeutics
- Enrolled: 101

## Sources

- ClinicalTrials.gov NCT05972720: https://clinicaltrials.gov/study/NCT05972720

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Firicabtagene autoleucel](https://onco.cc/drugs/firicabtagene-autoleucel/)
- companies: [CARGO Therapeutics](https://onco.cc/companies/cargo-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05972720.json